Application of estimand framework in ICH E9 (R1) to safety evaluation

被引:3
|
作者
Wang, Xuelong [1 ]
Yang, Ping [2 ]
Yuan, Shuai S. [3 ]
Wang, William W. B. [1 ]
机构
[1] Merck & Co Inc, BARDS, Rahway, NJ 07065 USA
[2] MSD China Holding Co Ltd, BARDS, Shanghai, Peoples R China
[3] GSK, Oncol Stat, Collegeville, PA USA
关键词
Safety; estimand framework; intercurrent events; oncology trial; pooled data analysis;
D O I
10.1080/10543406.2023.2189452
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Defining the right question of interest is important to a clinical study. ICH E9 (R1) introduces the framework of an estimand and its five attributes, which provide a basis for connecting different components of a study with its clinical questions. Most of the applications of the estimand framework focus on efficacy instead of safety assessment. In this paper, we expand the estimand framework into the safety evaluation and compare/contrast the similarity and differences between safety and efficacy estimand. Furthermore, we present and discuss applications of a safety estimand to oncology trials and pooled data analyses. At last, we also discuss the potential usage of safety estimand to handle the impacts of COVID-19 pandemic on safety assessment.
引用
收藏
页码:476 / 487
页数:12
相关论文
共 50 条
  • [1] Application of estimand framework in ICH E9 (R1) to vaccine trials
    Fu, Rong
    Li, Hal
    Wang, Xuelong
    Shou, Qiong
    Wang, William W. B.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (04) : 502 - 513
  • [2] Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation
    Ionan, Alexei C.
    Paterniti, Miya
    Mehrotra, Devan, V
    Scott, John
    Ratitch, Bohdana
    Collins, Sylva
    Gomatam, Shanti
    Nie, Lei
    Rufibach, Kaspar
    Bretz, Frank
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 554 - 559
  • [3] The ICH E9(R1) Estimand Framework in the Context of Real-World Data and Observational Studies
    Husemoen, Lotte
    Morga, Antonia
    Remiro-Azocar, Antonio
    Kleinjung, Frank
    Rantell, Khadija Rerhou
    Besseghir, Amel
    Rosettani, Barbara
    Allignol, Arthur
    Vaitsiakhovich, Tatsiana
    Polavieja, Pepa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 553 - 554
  • [4] The estimands framework: a primer on the ICH E9(R1) addendum
    Kahan, Brennan C.
    Hindley, Joanna
    Edwards, Mark
    Cro, Suzie
    Morris, Tim P.
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 384
  • [5] Estimands in observational studies: Some considerations beyond ICH E9 (R1)
    Li, Heng
    Wang, Chenguang
    Chen, Wei-Chen
    Lu, Nelson
    Song, Changhong
    Tiwari, Ram
    Xu, Yunling
    Yue, Lilly Q.
    PHARMACEUTICAL STATISTICS, 2022, 21 (05) : 835 - 844
  • [6] Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice
    Bohdana Ratitch
    James Bell
    Craig Mallinckrodt
    Jonathan W. Bartlett
    Niti Goel
    Geert Molenberghs
    Michael O’Kelly
    Pritibha Singh
    Ilya Lipkovich
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 324 - 341
  • [7] Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice
    Ratitch, Bohdana
    Bell, James
    Mallinckrodt, Craig
    Bartlett, Jonathan W.
    Goel, Niti
    Molenberghs, Geert
    O'Kelly, Michael
    Singh, Pritibha
    Lipkovich, Ilya
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 324 - 341
  • [8] Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework
    Mitroiu, Marian
    Teerenstra, Steven
    Rengerink, Katrien Oude
    Petavy, Frank
    Roes, Kit C. B.
    PHARMACEUTICAL STATISTICS, 2022, 21 (05) : 1037 - 1057
  • [9] Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice
    Mallinckrodt, C. H.
    Bell, J.
    Liu, G.
    Ratitch, B.
    O'Kelly, M.
    Lipkovich, I
    Singh, P.
    Xu, L.
    Molenberghs, G.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 353 - 364
  • [10] Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice
    C. H. Mallinckrodt
    J. Bell
    G. Liu
    B. Ratitch
    M. O’Kelly
    I. Lipkovich
    P. Singh
    L. Xu
    G. Molenberghs
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 353 - 364